DDInter1042 DDInter44
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
Alfuzosin {u} (Compound) resembles {v} (Compound) Terazosin
Alfuzosin {u} (Compound) resembles {v} (Compound) Prazosin
Alfuzosin {u} (Compound) binds {v} (Gene) ADRA1A
Alfuzosin {u} (Compound) upregulates {v} (Gene) PAK1
Alfuzosin {u} (Compound) downregulates {v} (Gene) RBM34
Alfuzosin {u} (Compound) causes {v} (Side Effect) Coronary artery disease
Alfuzosin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabilone
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Alfuzosin {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Alfuzosin (Compound) resembles Terazosin (Compound)
Alfuzosin (Compound) resembles Prazosin (Compound)
Alfuzosin (Compound) binds ADRA1A (Gene)
Alfuzosin (Compound) upregulates PAK1 (Gene)
Alfuzosin (Compound) downregulates RBM34 (Gene)
Alfuzosin (Compound) causes Coronary artery disease (Side Effect)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Alfuzosin may lead to a major life threatening interaction when taken with Cobicistat